Literature DB >> 29066112

Costs and Risk Factors for Hospital Readmission After Periprosthetic Knee Fractures in the United States.

Russell A Reeves1, William W Schairer2, David S Jevsevar3.   

Abstract

BACKGROUND: Periprosthetic fractures (PPFX) around total knee arthroplasty (TKA) are devastating complications with significant morbidity. With growing healthcare costs, hospital readmissions have become a marker for quality healthcare delivery. However, little is known about the risk factors or costs associated with readmission after treatment of PPFX. We sought to identify the patient demographics, prevalence of treatment types (open reduction internal fixation [ORIF] vs revision TKA), 30 and 90-day readmission rates, costs of initial treatment and readmission, and risk factors for readmission.
METHODS: We used the 2013 Nationwide Readmissions Database to select patients who underwent TKA, revision TKA, and treatment of PPFX with either ORIF or revision TKA. The 90-day readmission rate was determined through a survival analysis, and risk factors were identified using a cox proportional hazards model that adjusted for patient and hospital characteristics.
RESULTS: We identified 1526 patients with PPFX treated with ORIF and 1458 treated with revision TKA. Ninety-day readmissions were 20.5% and 21.8%, respectively. Patients with ORIF were more often female and had multiple medical comorbidities. Patient factors associated with readmission included advanced age, male gender, comorbidities, discharge to a skilled nursing facility or home with health aide, and Medicare or Medicaid insurance. Treatment at a teaching hospital was the only hospital-associated risk factor identified. ORIF cost USD 25,539 and revision THA cost USD 37,680, with associated readmissions costing 15,269 and 16,806, respectively.
CONCLUSION: PPFX results in greater costs compared to primary and revision TKA. This study highlights risk factors for readmission after PPFX treatment.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  arthroplasty; cost; fracture; knee; periprosthetic; readmission

Mesh:

Year:  2017        PMID: 29066112     DOI: 10.1016/j.arth.2017.09.024

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  6 in total

1.  Periprosthetic joint infection is the main reason for failure in patients following periprosthetic fracture treated with revision arthroplasty.

Authors:  Janna van den Kieboom; Venkatsaiakhil Tirumala; Liang Xiong; Christian Klemt; Young-Min Kwon
Journal:  Arch Orthop Trauma Surg       Date:  2021-05-15       Impact factor: 3.067

2.  DXA evaluation of femoral bone mineral density and cortical width in patients with prior total knee arthroplasty.

Authors:  T Blaty; D Krueger; R Illgen; M Squire; B Heiderscheit; N Binkley; P Anderson
Journal:  Osteoporos Int       Date:  2018-08-31       Impact factor: 4.507

3.  The projected volume of primary and revision total knee arthroplasty will place an immense burden on future health care systems over the next 30 years.

Authors:  Manuel Weißenberger; Alexander Klug; Yves Gramlich; Maximilian Rudert; Philipp Drees; Reinhard Hoffmann; Karl Philipp Kutzner
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2020-07-15       Impact factor: 4.342

4.  Projections and Epidemiology of Revision Hip and Knee Arthroplasty in the United States to 2030.

Authors:  Andrew M Schwartz; Kevin X Farley; George N Guild; Thomas L Bradbury
Journal:  J Arthroplasty       Date:  2020-02-19       Impact factor: 4.757

5.  Is the time to revision surgery after peri-prosthetic fracture of the knee associated with increased rates of post-operative complications?

Authors:  Venkat Boddapati; Michael B Held; Nathan J Lee; Jeffrey A Geller; H John Cooper; Roshan P Shah
Journal:  Arthroplast Today       Date:  2019-06-29

Review 6.  Review of patient-reported outcomes in periprosthetic distal femur fractures after total knee arthroplasty: a plate or intramedullary nail?

Authors:  Dustin Rinehart; Tyler Youngman; Junho Ahn; Michael Huo
Journal:  Arthroplasty       Date:  2021-06-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.